After struggling through a rough patch, the biotech industry seems to be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. Insiders, especially beneficial owners, have been showing their love as well, and some of the largest insider purchases in the past week or so have been in biotech stocks.
Here are some of the most notable insider purchases that were reported recently.
This post originally appeared at 24/7 Wall St.